European regulators have prohibited the already-implemented $7.1 billion merger of Illumina and GRAIL, stating that the deal “would have stifled innovation, and reduced choice in the emerging market for blood-based early cancer detection tests.”
FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.
